Halocur
halofuginone
Table of contents
Overview
Halocur is a veterinary medicine used to prevent or reduce diarrhoea caused by an organism called Cryptosporidium parvum in newborn calves. C. parvum is a parasite belonging to the ‘protozoa’ family that invades the digestive system, causing diarrhoea. The infection is known as cryptosporidiosis.
The medicine contains the active substance halofuginone.
Authorisation details
Product details | |
---|---|
Name |
Halocur
|
Agency product number |
EMEA/V/C/000040
|
Active substance |
halofuginone
|
International non-proprietary name (INN) or common name |
halofuginone
|
Species |
Calves, newborn
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QP51AX08
|
Publication details | |
---|---|
Marketing-authorisation holder |
Intervet International BV
|
Revision |
9
|
Date of issue of marketing authorisation valid throughout the European Union |
29/10/1999
|
Contact address |
Intervet International B.V.
Wim de Körverstraat 35 5831 AN Boxmeer The Netherlands |
Product information
16/08/2019 Halocur - EMEA/V/C/000040 - IB/0016
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antiprotozoals
Therapeutic indication
In newborn calves
Prevention of diarrhoea due to diagnosed Cryptosporidium parvum in farms with history of cryptosporidiosis.
Administration should start in the first 24 to 48 hours of age.
Reduction of diarrhoea due to diagnosed Cryptosporidium parvum.
Administration should start within 24 hours after the onset of diarrhoea.
In both cases, the reduction of oocyst excretion has been demonstrated.